Predictors of success of repeated injections of single-dose methotrexate regimen for tubal ectopic pregnancy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, GJ | - |
dc.contributor.author | Lee, SH | - |
dc.contributor.author | Shin, JW | - |
dc.contributor.author | Lee, NW | - |
dc.contributor.author | Kim, T | - |
dc.contributor.author | Kim, HJ | - |
dc.contributor.author | Lee, KW | - |
dc.date.accessioned | 2021-09-09T06:39:18Z | - |
dc.date.available | 2021-09-09T06:39:18Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2006-02 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/123167 | - |
dc.description.abstract | The purpose of this study is to evaluate predictors of success of repeated injections of methotrexate in the single-dose regimen for the treatment of tubal ectopic pregnancy. All patients who had ectopic tubal pregnancy and were treated with a single dose regimen were retrospectively identified. 126 patients were treated with methotrexate. Among them, 39 patients were adequate for this study. 33 were treated with the 2nd dose and 27 were successfully cured. Additionally, 6 who were injected with the 3rd dose were all cured as well. Therefore, in our study, the success rate for the repeated injections of methotrexate was found to be 84.6% (33/39). The mean initial beta-hCG level was significantly lower in patients who were successfully treated than in patients who failed (3915.3 +/- 3281.3 vs. 8379.7 +/- 2604.4 IU/mL, p<0.05). The success rate is 96% when the beta-hCG level is less than 6,000 IU/mL and is 58% when beta-hCG is greater than 6,000 IU/mL (0R=18.57, 95% CI 1.86-185.89). The initial beta-hCG level is the only factor that has significant meaning as predictor of success of repeated injections of methotrexate in the single-dose regimen. Repeated injections of methotrexate may be particularly effective when the initial beta-hCG level is below 6,000 IU/mL. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.subject | HUMAN CHORIONIC-GONADOTROPIN | - |
dc.subject | SYSTEMIC METHOTREXATE | - |
dc.subject | CLINICAL-TRIAL | - |
dc.subject | PATTERNS | - |
dc.title | Predictors of success of repeated injections of single-dose methotrexate regimen for tubal ectopic pregnancy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, SH | - |
dc.identifier.doi | 10.3346/jkms.2006.21.1.86 | - |
dc.identifier.scopusid | 2-s2.0-33144462088 | - |
dc.identifier.wosid | 000235694000017 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.21, no.1, pp.86 - 89 | - |
dc.relation.isPartOf | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 86 | - |
dc.citation.endPage | 89 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001115769 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | HUMAN CHORIONIC-GONADOTROPIN | - |
dc.subject.keywordPlus | SYSTEMIC METHOTREXATE | - |
dc.subject.keywordPlus | CLINICAL-TRIAL | - |
dc.subject.keywordPlus | PATTERNS | - |
dc.subject.keywordAuthor | pregnancy, ectopic | - |
dc.subject.keywordAuthor | methotrexate | - |
dc.subject.keywordAuthor | single-dose regimen | - |
dc.subject.keywordAuthor | repeated injections | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.